Biotech Values

[mcbio]

Re: CYP-1020 trial sites

One thing that bothered me with regards to the EAGLE trial was that only 2 sites were located in the US (see slide below). I asked the CEO at the time (Dr. Laster) and the reason he gave was as expected - cost. However, he also told me later that the data were similar in terms of response, efficacy and AE for different sites and historical data of Risperidone.

Thanks for the added cautionary color here genisi. For some reason, I thought the EAGLE trial involved a greater proportion of U.S. sites. Hopefully we can take Dr. Laster's comments at face value. Does the fact that almost half of the U.S. patients dropped out of the study concern you? Is that the norm for Risperidone? Also, no U.S. patients enrolled to extension, but I guess that was due to cost considerations.